Your fact-checks will appear here
Health organization seeking to cure and treat cancer
Executive summary: Having receptive anal sex does not directly “give you cancer,” but it increases exposure to , which is the dominant cause of anal cancer; most HPV infections clear on their own, and...
PSA elevations from prostatitis are usually transient and clinicians commonly wait 4–8 weeks after treatment or symptom resolution before retesting PSA; guidelines and reviews recommend repeat testing...
Recent studies and guideline summaries show clinicians have routinely checked PSA 6–8 weeks (1.5–2 months) after radical prostatectomy, but new large analyses argue waiting at least three months reduc...
Major public-health bodies find little direct evidence that radiofrequency (RF) emissions from cell towers cause cancer in people; the FCC and American Cancer Society say there is “very little evidenc...
Available U.S. estimates place the lifetime probability of being diagnosed with invasive cancer at roughly 39% for women and 40% for men (about 38.9%–41% overall depending on the source and method) . ...
Available reporting and guidelines say mammograms are X‑ray exams used to detect breast cancer early and that screening has been linked to large reductions in breast‑cancer deaths; the U.S. Preventive...
Recent large-cohort evidence and guideline summaries disagree about the ideal timing for the first definitive post‑prostatectomy PSA check: traditional practice often measures PSA at about 1.5–2 month...
Congress played a mixed, active role in both blocking and enabling portions of the Trump administration’s proposed cuts to cancer and biomedical research: courts and Democratic-led House actions helpe...
Anal cancer often begins with subtle, easily missed signs — most commonly minor rectal bleeding — and early symptoms frequently mimic benign conditions such as hemorrhoids or fissures, which can delay...
After robotic radical prostatectomy the prostate — the main source of PSA — is removed and PSA is expected to fall to very low or undetectable levels within weeks to a few months; most guidelines and ...
After surgery (radical prostatectomy) for localized prostate cancer, most men do not die of the disease: five‑year relative survival for localized/regional prostate cancer exceeds 99% . Estimates of b...
After radical prostatectomy, most clinical sources say PSA falls to very low or undetectable levels within weeks to a few months — commonly cited windows are “within a couple of months” or roughly 6–8...
After radical prostatectomy, 20–40% of men will see PSA rise within 10 years; a rising PSA after surgery typically triggers evaluation and often salvage/local therapy such as radiation to the prostate...
Stage I breast cancer is highly survivable: five‑year relative survival for localized (stage I) disease is about 99% according to multiple U.S. cancer organizations and datasets (American Cancer Socie...
After radical prostatectomy PSA usually falls to very low or undetectable levels within weeks to a few months; major guideline thresholds and recent studies disagree on exact cutoffs and timing. Sourc...
After radical prostatectomy (RP) PSA typically falls to a very low or undetectable level within about 2 months, but recent large-cohort research and several specialist bodies argue for waiting at leas...
The Cancer Moonshot began under the Obama administration in 2016 with $1.8 billion in supplemental funding authorized by the 21st Century Cures Act and an initial $300 million first installment (Beau ...
About 2.04 million new cancer cases and roughly 618,120 cancer deaths are projected in the United States in 2025, meaning on average about 5,600 new diagnoses and 1,700 deaths per day . Lifetime and a...
Most clinical and patient-facing sources say PSA after radical prostatectomy typically falls to a very low or undetectable level within about 6–8 weeks to 2 months; common clinical thresholds discusse...
Available sources document program eliminations, funding cuts and some terminated grants tied to policy shifts and budget changes between 2017–2020 — most prominently charity-driven cuts at Cancer Res...